Prostate Cancer: Double VS triplet therapy in mHSPC - Urology Cheatsheets
![Definition of high and low volume, and risk in CHAARTED [54-56] and... | Download Scientific Diagram](https://www.researchgate.net/profile/Thomas-Lam-3/publication/344701128/figure/tbl2/AS:947382543974400@1602885008617/Key-findings-hormonal-treatment-combined-with-chemotherapy-in-men-presenting-with_Q320.jpg "Definition of high and low volume, and risk in CHAARTED [54-56] and... | Download Scientific Diagram")
Definition of high and low volume, and risk in CHAARTED [54-56] and... | Download Scientific Diagram
Prostate Cancer Review
ASCO GU 2020: Targeted Therapy in the Context of Low Volume Metastatic Prostate Cancer
Non-systemic Treatment for Patients With Low-volume Metastatic Prostate Cancer
Patients' distribution according to LATITUDE and CHAARTED risk criteria... | Download Scientific Diagram
Treatment of Metastatic Prostate Cancer in 2018.,JAMA Oncology - X-MOL
Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients: A Systematic Review and Network Meta-analysis - European Urology Focus
EAU 2018: Variation in Prevalence of High and Low Volume Metastatic Prostate Cancer from the Original Comparison in the STAMPEDE Trial
Non-systemic Treatment for Patients With Low-volume Metastatic Prostate Cancer
Impact of high-volume disease in Asian population with newly diagnosed metastatic prostate cancer Cheng YT, Hong JH, Lu YC, Pu YS, Huang CY, Huang KH, Liu SP, Chen CH - Urol Sci
Targeting Metastatic Hormone Sensitive Prostate Cancer: Chemohormonal Therapy and New Combinatorial Approaches | Journal of Urology
Cancers | Free Full-Text | Where Do We Stand in the Management of Oligometastatic Prostate Cancer? A Comprehensive Review
Going towards a precise definition of the therapeutic management of de-novo metastatic castration sensitive prostate cancer patients: How prognostic classification impact treatment decisions - ScienceDirect
![Definition of high and low volume, and risk in CHAARTED [54-56] and... | Download Scientific Diagram](https://www.researchgate.net/profile/Thomas-Lam-3/publication/344701128/figure/tbl1/AS:947382543978497@1602885008589/Definition-of-high-and-low-volume-and-risk-in-CHAARTED-54-56-and-LATITIDE-57-based.png "Definition of high and low volume, and risk in CHAARTED [54-56] and... | Download Scientific Diagram")
Definition of high and low volume, and risk in CHAARTED [54-56] and... | Download Scientific Diagram
Bone Imaging in Metastatic Castration-resistant Prostate Cancer; Where do we Stand | Bentham Science
Frontiers | Comparing the Survival Outcomes of Radical Prostatectomy Versus Radiotherapy for Patients With De Novo Metastasis Prostate Cancer: A Population-Based Study
APCCC 2019: Which Systemic Therapy for Which Patients with Newly Diagnosed Metastatic Prostate Cancer?
Untreated Metastatic Prostate Cancer - 2021 Prostate Cancer Patient Conference - YouTube
Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer - eBioMedicine
Oligometastatic Prostate Cancer: A Shrinking Subset or an Opportunity for Cure? | American Society of Clinical Oncology Educational Book
The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact | Nature Communications
Prostate cancer - The Lancet
EAU 2021: Apalutamide for Metastatic Castration-Sensitive Prostate Cancer: Outcomes in High-Volume and Low-Volume Disease From the TITAN Final Analysis
PSMA PET for the Assessment of Metastatic Hormone-Sensitive Prostate Cancer Volume of Disease | Journal of Nuclear Medicine
Oligometastatic cancer: Total Eradication Treatment TET) Trials — Cancer Ecology Center
